Skip to main content
. Author manuscript; available in PMC: 2013 Jun 26.
Published in final edited form as: Clin Cancer Res. 2012 Nov 13;19(1):106–117. doi: 10.1158/1078-0432.CCR-12-2143

Figure 4.

Figure 4

IL-15 sustains the antitumor effects of EBV-CTLs in the presence of Tregs. Tregs were tested for their ability to inhibit EBV-CTL antitumor activity in the presence or absence of cytokines in coculture experiments. A, a representative coculture experiment in which EBV-CTLs generated from a healthy donor were incubated with autologous LCL with or without Tregs freshly isolated from healthy donors and cytokines. Residual tumor cells were enumerated by flow cytometry based on the expression of CD19 by day 7 of culture. The graph summarizes the percentage of residual tumor cells (mean ± SEM) for the 6 independent experiments. *, P < 0.01. B, a representative coculture experiment in which EBV-CTLs generated from a patient with Hodgkin lymphoma were incubated with autologous LCL with or without Treg-clones and cytokines. The graph summarizes the percentage of residual tumor cells (mean ± SD) for 3 independent experiments. *, P < 0.01.